Roche delivery platforms for biotherapeutics to treat neuroinflammation and neurodegeneration
Eduard Urich Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Switzerland
Biotherapeutics such as monoclonal antibodies have been successful in disease areas such as autoimmunity and oncology. However, their potential, for treating central nervous system (CNS) sequestered inflammation and malignancies, has been limited due to extremely low brain exposure. A therapeutic antibody has a very restricted blood brain barrier (BBB) penetration and therefore its therapeutic activity is very low, especially for CNS compartmentalized immune cells, malignancies and neurodegenerative processes behind an intact BBB. I will describe our recent novel antibody engineering platforms; including our Brain Shuttle technology that utilizes receptor-mediated transcytosis to cross an intact BBB. Experimental data will illustrate the absolute requirement to cross the BBB to access proteinopathies in the brain and remove autoimmune and tumor cells within the brain parenchyma and cerebrospinal fluid.
Credits: None available.
You must be logged in and own this product in order to